From April 2 to 3, the CGT Asia 2024 - 5th Asia Cell & Gene Therapy Innovation Summit was successfully held in Shanghai. Over the two-day summit, nearly 100 authoritative experts from government, industry, academia and research sectors gathered across five venues. Focusing on hot topics such as the layout of cell therapy industrialization and commercialization modules, the overcoming of challenges in viral vectors, the implementation of comprehensive application schemes for gene therapy products, and the development of next-generation oncolytic viruses, they delivered rich and wonderful content to the on-site audience.

XMJ participated in the exhibition jointly with two well-known brands, Mirus and Astrea Bioseparations. Covering the whole process from upstream transfection to downstream purification, XMJ provided new technologies and efficient solutions for improving the yield, viability and purity of viral vectors, helping CGT projects achieve steady and long-term development.

At the booth, we exhibited the featured products of Mirus and Astrea Bioseparations, which attracted a large number of exhibition guests to stop and consult. The manufacturers dispatched professional technical support staff to patiently answer customers' questions on-site, and provided customers with a variety of solutions regarding aspects such as how to improve transfection efficiency and viral vector yield, as well as how to enhance viral vector purification efficiency and recovery rate.

In addition, Dr. Yu Shengli, Head of Astrea Bio China, delivered a presentation titled "Upstream Transfection + Downstream Purification: Comprehensively Improving the Yield, Viability, and Purity of Viral Vectors to Facilitate Efficient Viral Vector Production" at Cell Therapy Venue B. The presentation not only explained optimization solutions for cost reduction and efficiency enhancement throughout the process from upstream transfection to downstream purification but also demonstrated the outstanding characteristics of Mirus and Astrea Bio products through a wealth of customer feedback data, providing new insights and options for CGT project R&D and process development. (Please contact XMJ to request the presentation PPT if needed.)

Founded in 1995, Mirus has always been committed to providing better methods and more efficient tools for gene delivery. With over 25 years of in-depth efforts in the transfection field, it has achieved multiple technological breakthroughs and has become a global leader and trusted brand in the nucleic acid delivery sector. Mirus' team of scientists continuously pushes the boundaries of transfection technology and has launched VirusGEN® Transfection Reagent and RevIT? Enhancer. These products further increase AAV/LV yields, help reduce costs and improve efficiency in biotherapeutic drug development, and empower customers in the CGT field.

Astrea Bioseparations was incubated at the University of Cambridge in 1987. With over 30 years of experience in the R&D and production of chromatographic media, it is a world-class supplier of chromatographic media products and services. To date, more than 21 manufacturing processes using Astrea's products have obtained approvals from the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency).

Astrea Bioseparations has 3 R&D and production bases worldwide, focusing on providing industry-leading chromatographic media and technical services for the biopharmaceutical (large molecule) and CGT (Cell & Gene Therapy) sectors. Its novel nanofiber technology-based product, LentiHERO, features high capacity, high flow rate, and high recovery rate, facilitating the efficient purification of lentiviral vectors.

Beijing XMJ Scientific Co., Ltd. is the authorized distributor of Mirus and Astrea Bioseparations in China, providing users with comprehensive technical support and after-sales service. If you are interested in the above-mentioned products, please feel free to send email to info@xmjsci.com or visit the website www.gp82.cn for more information.